Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Mustang Bio makes the NASDAQ top percentage gainers list on FDA news, currently trading at $3.56. up $2.37, gaining 199% on volume of over 152 Million shares as of this report. The stock has a day's ...

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

Investing.com -- Mustang Bio Inc (NASDAQ: MBIO) stock surged over 78% after the U.S. Food and Drug Administration granted orphan drug designation to its MB-101 treatment for recurrent diffuse and ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...